Projects per year
Personal profile
Research expertise
Bouke de Jong completed her training in clinical infectious diseases at the Universities of Amsterdam, Nevada, and Stanford. Her focus on the molecular epidemiology of tuberculosis in San Francisco brought her to The Gambia, where she developed an interest in TB transmission and the M. tuberculosis complex member Mycobacterium africanum. After an MSc in epidemiology at the Netherlands Institute for Health Sciences and PhD at the University of Amsterdam, Dr. de Jong joined the Division of Infectious Diseases at New York University as Assistant Professor in 2007.
Since 2010 Dr. de Jong heads the Unit of Mycobacteriology at the Institute of Tropical Medicine. Besides tuberculosis, she studies Buruli Ulcer and leprosy, focusing on improved diagnostics and treatment, as well as molecular epidemiological studies on the impact of public health interventions to reduce transmission, for which she was supported by an ERC starting grant. Together with a very capable team she (co)supervises PhD students from different (endemic) countries.
Research lines
- Improved molecular (resistance) diagnostics for leprosy, Buruli ulcer, and tuberculosis
- Phylogeography, phylodynamics, and molecular epidemiology of M. ulcerans, M. tuberculosis, and M. leprae in the context of intervention studies
- Optimized treatment for M. tuberculosis
Education/Academic qualification
Medicine, PhD
Medicine, MD
Epidemiology, MSc
Fingerprint
Dive into the research topics where Bouke de Jong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Omics Data Integration to Predict Drug Resistance in Mycobacterium tuberculosis
Snobre, J., de Jong, B. & Buyl, R.
27/04/22 → …
Project: PhD-project
-
Rapid diagnosis of Mycobacterium tuberculosis resistance, beyond rifampicin
Massou, F. A. T., de Jong, B., Rigouts, L., Affolabi, D. & Meehan, C. J.
1/01/22 → …
Project: PhD-project
-
Laboratory and bioinformatics innovations towards culture-free whole genome sequencing of Mycobacterium tuberculosis for clinical care
Krausser, L., de Jong, B. & Van Rie, A.
30/06/21 → …
Project: PhD-project
-
Curbing rifampicin-resistant tuberculosis in Rwanda and beyond
Cuella Martin, I., de Jong, B. & Rigouts, L.
30/06/21 → …
Project: PhD-project
Research output
-
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
Van Deun, A., Bola, V., Lebeke, R., Kaswa, M., Hossain, M. A., Gumusboga, M., Torrea, G., De Jong, B. C., Rigouts, L. & Decroo, T., 2022, In : JAC-Antimicrobial Resistance. 4, 2, 9 p., dlac037.Research output: Contribution to journal › A1: Web of Science-article
-
Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: a retrospective cohort study
Souleymane, M. B., Decroo, T., Mamadou, S., Soumana, A., Lawan, I. M., Gagara-Issoufou, A., Adehossi, E., Ortuño-Gutiérrez, N., Lynen, L., Rigouts, L., de Jong, B. C., Van Deun, A. & Piubello, A., 2022, In : International Health.Research output: Contribution to journal › A1: Web of Science-article
-
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century
Ngabonziza, J. C. S., Rigouts, L., Torrea, G., Decroo, T., Kamanzi, E., Lempens, P., Rucogoza, A., Habimana, Y. M., Laenen, L., Niyigena, B. E., Uwizeye, C., Ushizimpumu, B., Mulders, W., Ivan, E., Tzfadia, O., Muvunyi, C. M., Migambi, P., Andre, E., Mazarati, J. B., Affolabi, D. & 6 others, , 2022, In : Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 27, 100299.Research output: Contribution to journal › A1: Web of Science-article
-
Pretomanid for tuberculosis: a systematic review
Gils, T., Lynen, L., de Jong, B. C., Van Deun, A. & Decroo, T., 2022, In : Clinical Microbiology and Infection. 28, 1, p. 31-42 12 p.Research output: Contribution to journal › A1: Web of Science-article
-
Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
Decroo, T., Jai, K., Aung, M., Hossain, M. A., Gumusboga, M., Ortuno-Gutierrez, N., de Jong, B. C. & Van Deun, A., 2021, In : European Respiratory Journal.Research output: Contribution to journal › A1: Web of Science-article